Registration Validity and Renewal: 5-Year Cap, 3 Years for Implants

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The rule for Israeli registration periods is a cap plus taking the shorter: Section 12 of the regulations provides that the registration period does not exceed 5 years, and 3 years for implants; where the device is already registered in a Recognised State, the validity runs to the expiry date of that state’s registration or licence, and in no case beyond 5 years from the date of Israeli registration. On renewal, Section 8 of the law requires the application to be submitted at least 4 months before expiry, and once submitted the registration is deemed extended until the Director decides. GRZAN’s practical estimate is: the real ceiling is the reference-country certificate expiry date, not the 5 years. Renewal planning should therefore start from the earliest expiry date among the reference certificate, the AMAR registration and the import licence.

  • Registration period: 5-year cap; implants 3 years (Section 12).
  • Reference-country registrations: validity ends at that state’s expiry date, capped at 5 years from Israeli registration.
  • Renewal applications must be filed at least 4 months before expiry (Section 8 of the law).
  • A filed renewal application keeps the registration valid until the Director decides.
  • The operative ceiling is usually the reference-country certificate expiry date.

2. Legal basis

The validity rules sit in the 2013 regulations, while the renewal mechanics and the post-expiry window sit in the parent law. The elements cited in this article are listed below.

Name of legislationMedical Equipment Regulations (Registration of Medical Equipment in the Register and Renewal thereof), 5773-2013
Number5773-2013
Publication date12 June 2013 (in force 30 days after publication)
Articles citedSection 12 (registration period: not exceeding 5 years; (1) implants 3 years; (2) devices registered in a reference state run to that state’s expiry and not more than 5 years from Israeli registration)
Parent lawMedical Equipment Law, 5772-2012, published 14 May 2012, Section 8 (renewal: at least 4 months in advance; deemed extended once filed until decision), Section 10 (continued marketing after non-renewal, excluding imports, not exceeding 2 years)
Companion provisionsSection 7 of the regulations (renewal applications), Section 8 of the regulations (notice of continued marketing for low-risk non-sterile devices)

3. Expert insights

One design feature of the Israeli validity regime stands out: the registration validity is tied to the reference-country approval. This is not administrative convenience but the inevitable consequence of the reliance mechanism – since the technical judgment comes from the reference state, once that state’s approval lapses, the Israeli registration loses its basis.

Three practical corollaries follow:

Corollary one: the CE certificate expiry date is the soft ceiling of the Israeli registration. Products holding an MDR CE certificate usually have a certificate valid for 5 years; where the remaining validity is less than 5 years, the Israeli registration expiry falls on the certificate expiry date. When planning several years ahead in Israel, a company must align with the certificate maintenance rhythm in the EU.

Corollary two: implants are separately downgraded. Section 12(1) of the regulations limits implants to 3 years, distinguishing them from the general 5 years. The downgrade reflects the regulator’s caution about the long-term risks of implantable devices, and it means implant companies face a higher renewal frequency and a heavier post-market reporting burden.

Corollary three: the deemed-extension mechanism on renewal is an important buffer. Section 8 of the law provides that as long as the renewal application is submitted at least 4 months before expiry, the registration is deemed to remain valid until the Director decides. This gives legal protection against review delays – on condition of timely filing. In the lapsed registrations GRZAN has handled, the overwhelming majority missed this 4-month window rather than failing the review.

Taken together, the three corollaries mean that expiry management in Israel is really a calendar problem spanning three jurisdictions. The Israeli registration, the reference-country certificate and the import licence each carry their own expiry logic, and the effective availability of the device on the Israeli market ends at whichever date arrives first. The renewal route chosen also matters: a renewal that follows the declaration route or a fast track closes much sooner than a standard review, which is why the start-of-renewal date should be fixed by the earliest expiry date on the dashboard rather than by the nominal 5-year registration period.

4. Practical recommendations

  • Build a three-certificate expiry dashboard: put the expiry dates of the CE/FDA certificate, the AMAR registration and the import licence on one sheet, and schedule renewals backwards from the earliest date.
  • Schedule on the shortest: start of renewal = 6 months before the earliest expiry (the 4-month statutory window plus a 2-month preparation buffer – a practical estimate).
  • Manage implants separately: set renewal reminders for implantable products on a 3-year cycle instead of the 5-year habit.
  • Advance the reference-country renewal in parallel: delays in CE or FDA renewal directly compress the usable Israeli registration period, so run both renewals as one project.

5. Verification checklist

  • □ The AMAR registration certificate expiry date has been recorded, distinguishing implants (3 years vs 5 years)
  • □ The reference-country approval expiry date has been recorded as the de facto ceiling of the Israeli registration
  • □ A renewal-start reminder is set 6 months before expiry
  • □ The renewal application is filed no later than 4 months before expiry
  • □ The renewal route has been determined by risk class (declaration / fast track / standard)
  • □ Post-market reporting for Class III and Class D IVDs has begun

Regulatory information verified as of 29 October 2026. All law names, numbers, publication dates and article numbers cited in this article were checked on that date against the official Israeli legal database and authoritative public sources; AMAR procedural documents are updated frequently, so before any formal submission please rely on the current version published on the Ministry of Health website.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Israeli market. Our team manages Ministry of Health (MOH) registrations under the Medical Devices Law 5772-2012, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail